https://orcid.org/0000-0002-4692-7499
References
- Cao L, Weetall M, Bombard J, Qi H, Arasu T, Lennox W, Hedrick J, Sheedy J, Risher N, Brooks PC, et al. 2016. Discovery of novel small molecule inhibitors of VEGF expression in tumour cells using a cell-based high throughput screening platform. PLoS One. 11(12):e0168366. Available from https://doi.org/http://dx.doi.org/10.1371/journal.pone.0168366
- Cao L, Weetall M, Trotta C, Cintron K, Ma J, Kim MJ, Furia B, Romfo C, Graci JD, Li W, et al. 2019. Targeting of hematologic malignancies with PTC299, a novel potent inhibitor of dihydroorotate dehydrogenase with favourable pharmaceutical properties. Mol Cancer Ther. 18(1):3–16.
- Ignacio RAB, Lee JY, Rudek MA, Dittmer DP, Ambinder RF, Krown SE, AIDS Malignancy Consortium (AMC)-059 Study Team 2016. A phase 1b/pharmacokinetic trial of PTC299, a novel post transcriptional VEGF inhibitor, for AIDS-related Kaposi’s sarcoma: AIDS Malignancy Consortium trial 059. J Acquir Immune Defic Syndr. 72 (1):52–57.
- Kong R, Ma J, Hwang S, Moon YC, Welch EM, Weetall M, Colacino JM, Almstead N, Babiak J, Goodwin E. 2020. In vitro metabolism, reaction phenotyping, enzyme kinetics, CYP inhibition and induction potential of ataluren. Pharmacol Res Perspect. 8(2):e00576.. Available from https://doi.org/https://doi.org/10.1002/prp2.576.
- Luban J, Sattler RA, Mühlberger E, Graci JD, Cao L, Weetall M, Trotta C, Colacino JM, Bavari S, Strambio-De-Castillia C, et al. 2021. The DHODH inhibitor PTC299 arrests SARS-CoV-2 replication and suppresses induction of inflammatory cytokines. Virus Res. 292:198246.
- Packer RJ, Rood BR, Turner DC, Stewart CF, Fisher M, Smith C, Young-Pouissant T, Goldman S, Lulla R, Banerjee A, et al. 2015. Phase I and pharmacokinetic trial of PTC299 in pediatric patients with refractory or recurrent central nervous system tumors: a PBTC study. J Neurooncol. 121(1):217–224.
- Paris BL, Ogilvie BW, Scheinkoenig JA, Ndikum-Moffor F, Gibson R, Parkinson A. 2009. In vitro inhibition and induction of human liver cytochrome P450 enzymes by milnacipran. Drug Metab Dispos. 37(10):2045–2054.
- U.S. Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research 2020. Guidance for Industry: In Vitro Drug Interaction Studies — Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions. January 2020. Available from https://www.fda.gov/media/134582/download.
- Weetall M, Davis T, Elfring G, Northcutt V, Cao L, Moon YC, Riebling P, Dali M, Hirawat S, Babiak J, et al. 2016. Phase 1 study of safety, tolerability, and pharmacokinetics of PTC299, an inhibitor of stress-regulated protein translation. Clin Pharmacol Drug Dev. 5(4):296–305.